147 related articles for article (PubMed ID: 38375823)
21. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
22. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
Peeraphatdit TB; Wang J; Odenwald MA; Hu S; Hart J; Charlton MR
Hepatology; 2020 Jul; 72(1):315-329. PubMed ID: 32167613
[TBL] [Abstract][Full Text] [Related]
23. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy.
Tsung I; Dolan R; Lao CD; Fecher L; Riggenbach K; Yeboah-Korang A; Fontana RJ
Aliment Pharmacol Ther; 2019 Oct; 50(7):800-808. PubMed ID: 31309615
[TBL] [Abstract][Full Text] [Related]
24. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
Hirasawa Y; Yoshimura K; Matsui H; Kubota Y; Ishida H; Arai J; Sakaki M; Oguro N; Shida M; Taniguchi M; Hamada K; Ariizumi H; Ishiguro T; Ohkuma R; Sambe T; Horiike A; Imamura CK; Shiozawa E; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Tate G; Kobayashi S; Tsunoda T
Medicine (Baltimore); 2021 Jun; 100(23):e25774. PubMed ID: 34114983
[TBL] [Abstract][Full Text] [Related]
25. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury.
Chalasani NP; Maddur H; Russo MW; Wong RJ; Reddy KR;
Am J Gastroenterol; 2021 May; 116(5):878-898. PubMed ID: 33929376
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach.
Bessone F; Bjornsson ES
World J Hepatol; 2022 Jul; 14(7):1269-1276. PubMed ID: 36158917
[TBL] [Abstract][Full Text] [Related]
27. An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury.
Riveiro-Barciela M; Barreira-Díaz A; Salcedo MT; Callejo-Pérez A; Muñoz-Couselo E; Iranzo P; Ortiz-Velez C; Cedrés S; Díaz-Mejía N; Ruiz-Cobo JC; Morales R; Aguilar-Company J; Zamora E; Oliveira M; Sanz-Martínez MT; Viladomiu L; Martínez-Gallo M; Felip E; Buti M
Aliment Pharmacol Ther; 2024 Apr; 59(7):865-876. PubMed ID: 38327102
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.
Narayanaswami P; Sanders DB; Thomas L; Thibault D; Blevins J; Desai R; Krueger A; Bibeau K; Liu B; Guptill JT;
Lancet Neurol; 2024 Mar; 23(3):267-276. PubMed ID: 38365379
[TBL] [Abstract][Full Text] [Related]
29. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
Celsa C; Cabibbo G; Fulgenzi CAM; Scheiner B; D'Alessio A; Manfredi GF; Nishida N; Ang C; Marron TU; Saeed A; Wietharn B; Pinter M; Cheon J; Huang YH; Lee PC; Phen S; Gampa A; Pillai A; Vivaldi C; Salani F; Masi G; Roehlen N; Thimme R; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; El Tomb P; Ulahannan S; Parisi A; Chon HJ; Hsu WF; Stefanini B; Verzoni E; Giusti R; Veccia A; Catino A; Aprile G; Guglielmini PF; Di Napoli M; Ermacora P; Antonuzzo L; Rossi E; Verderame F; Zustovich F; Ficorella C; Di Pietro FR; Battelli N; Negrini G; Grossi F; Bordonaro R; Pipitone S; Banzi M; Ricciardi S; Laera L; Russo A; De Giorgi U; Cavanna L; Sorarù M; Montesarchio V; Bordi P; Brunetti L; Pinto C; Bersanelli M; Cammà C; Cortellini A; Pinato DJ
J Hepatol; 2024 Mar; 80(3):431-442. PubMed ID: 37972660
[TBL] [Abstract][Full Text] [Related]
30. Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
Björnsson HK; Gudbjornsson B; Björnsson ES
J Hepatol; 2022 Jan; 76(1):86-92. PubMed ID: 34487751
[TBL] [Abstract][Full Text] [Related]
31. [Hepatotoxicity induced by new immunosuppressants].
Toscano E; Cotta J; Robles M; Lucena MA; Andrade RJ
Gastroenterol Hepatol; 2010 Jan; 33(1):54-65. PubMed ID: 19889479
[TBL] [Abstract][Full Text] [Related]
32. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.
Beissert S; Werfel T; Frieling U; Böhm M; Sticherling M; Stadler R; Zillikens D; Rzany B; Hunzelmann N; Meurer M; Gollnick H; Ruzicka T; Pillekamp H; Junghans V; Bonsmann G; Luger TA
Arch Dermatol; 2007 Dec; 143(12):1536-42. PubMed ID: 18087004
[TBL] [Abstract][Full Text] [Related]
33. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.
Hountondji L; Ferreira De Matos C; Lebossé F; Quantin X; Lesage C; Palassin P; Rivet V; Faure S; Pageaux GP; Assenat É; Alric L; Zahhaf A; Larrey D; Witkowski Durand Viel P; Riviere B; Janick S; Dalle S; Maria ATJ; Comont T; Meunier L
JHEP Rep; 2023 Jun; 5(6):100719. PubMed ID: 37138674
[TBL] [Abstract][Full Text] [Related]
34. The use of tacrolimus in the management of checkpoint inhibitor immunotherapy-induced hepatitis.
McIlwaine S; Cullen A; Stratton L; Oladipo B; Cash J; Carser J; Braniff C
J R Coll Physicians Edinb; 2022 Mar; 52(1):20-23. PubMed ID: 36146973
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of immune checkpoint inhibitor-mediated liver injury.
Shojaie L; Ali M; Iorga A; Dara L
Acta Pharm Sin B; 2021 Dec; 11(12):3727-3739. PubMed ID: 35024302
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Inhibitors-Induced Hepatitis.
Tian Y; Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2018; 995():159-164. PubMed ID: 30539511
[TBL] [Abstract][Full Text] [Related]
37. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
Huffman BM; Kottschade LA; Kamath PS; Markovic SN
Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
[TBL] [Abstract][Full Text] [Related]
38. Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials.
Lynch C; Korpics MC; Katipally RR; Wu T; Bestvina CM; Pitroda S; Chmura SJ; Juloori A
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1519-1530. PubMed ID: 38199382
[TBL] [Abstract][Full Text] [Related]
39. The diagnosis and management of idiosyncratic drug-induced liver injury.
Hassan A; Fontana RJ
Liver Int; 2019 Jan; 39(1):31-41. PubMed ID: 30003672
[TBL] [Abstract][Full Text] [Related]
40. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
Li M; Wong D; Vogel AS; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Hepatology; 2022 Mar; 75(3):531-540. PubMed ID: 34709662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
